MX2016007848A - Forma de dosificacion resistente a alteraciones con perfil de liberacion bimodal fabricado mediante co-extrusion. - Google Patents
Forma de dosificacion resistente a alteraciones con perfil de liberacion bimodal fabricado mediante co-extrusion.Info
- Publication number
- MX2016007848A MX2016007848A MX2016007848A MX2016007848A MX2016007848A MX 2016007848 A MX2016007848 A MX 2016007848A MX 2016007848 A MX2016007848 A MX 2016007848A MX 2016007848 A MX2016007848 A MX 2016007848A MX 2016007848 A MX2016007848 A MX 2016007848A
- Authority
- MX
- Mexico
- Prior art keywords
- segment
- dosage form
- extrusion
- release profile
- tamper resistant
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 2
- 230000002902 bimodal effect Effects 0.000 title 1
- 238000001125 extrusion Methods 0.000 title 1
- 239000002831 pharmacologic agent Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13197503 | 2013-12-16 | ||
| PCT/EP2014/077748 WO2015091352A1 (en) | 2013-12-16 | 2014-12-15 | Tamper resistant dosage form with bimodal release profile manufactured by co-extrusion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016007848A true MX2016007848A (es) | 2016-09-07 |
Family
ID=49882823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016007848A MX2016007848A (es) | 2013-12-16 | 2014-12-15 | Forma de dosificacion resistente a alteraciones con perfil de liberacion bimodal fabricado mediante co-extrusion. |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20150164807A1 (enExample) |
| EP (1) | EP3082781A1 (enExample) |
| JP (2) | JP2016540798A (enExample) |
| AU (1) | AU2014365038B2 (enExample) |
| CA (1) | CA2933983A1 (enExample) |
| MX (1) | MX2016007848A (enExample) |
| WO (1) | WO2015091352A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201502077D0 (en) * | 2015-02-09 | 2015-03-25 | Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd | Improved hme technology |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3612211A1 (de) | 1986-04-11 | 1987-10-15 | Basf Ag | Kontinuierliches verfahren zum tablettieren |
| DE19710008A1 (de) * | 1997-03-12 | 1998-09-17 | Basf Ag | Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung |
| AU3024399A (en) | 1998-04-03 | 1999-10-25 | Bm Research A/S | Controlled release composition |
| US7141250B2 (en) | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
| WO2003024430A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Morphine polymer release system |
| DE10252667A1 (de) | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| ES2307003T3 (es) | 2003-03-26 | 2008-11-16 | Egalet A/S | Composiciones matriciales para el suministro controlado de sustancias medicamentosas. |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| WO2005016313A1 (de) | 2003-08-06 | 2005-02-24 | Grünenthal GmbH | Gegen missbrauch gesicherte darreichungsform |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE10360792A1 (de) | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| WO2005102286A1 (de) | 2004-04-22 | 2005-11-03 | Grünenthal GmbH | Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreinchungsform |
| WO2006002883A1 (de) | 2004-07-01 | 2006-01-12 | Grünenthal GmbH | Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreichungsform unter verwendung eines planetwalzenextruders |
| EP1765303B2 (de) | 2004-07-01 | 2022-11-23 | Grünenthal GmbH | Gegen missbrauch gesicherte, oral tablette |
| PL1786403T3 (pl) | 2004-07-01 | 2013-10-31 | Gruenenthal Gmbh | Doustna postać dawki zabezpieczona przed nadużywaniem zawierająca (1R, 2R)-3-(3-dimetyloamino-1-etylo0-2-metylo-propylo)fenol |
| JP4563787B2 (ja) * | 2004-12-10 | 2010-10-13 | 日立プラズマディスプレイ株式会社 | プラズマディスプレイ装置及びその制御方法 |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| JP5161075B2 (ja) | 2005-06-03 | 2013-03-13 | エガレット エイ／エス | 分散媒体の第１フラクションとマトリックスの第２フラクションを有し、第２フラクションが胃腸の液体に少なくとも部分的に最初に曝される固形の医薬組成物 |
| US20100172989A1 (en) | 2006-01-21 | 2010-07-08 | Abbott Laboratories | Abuse resistant melt extruded formulation having reduced alcohol interaction |
| US20090022798A1 (en) * | 2007-07-20 | 2009-01-22 | Abbott Gmbh & Co. Kg | Formulations of nonopioid and confined opioid analgesics |
| MX2008009267A (es) * | 2006-01-21 | 2008-10-09 | Abbott Gmbh & Co Kg | Forma farmaceutica y metodo para la administracion de farmacos de abuso. |
| US20090317355A1 (en) * | 2006-01-21 | 2009-12-24 | Abbott Gmbh & Co. Kg, | Abuse resistant melt extruded formulation having reduced alcohol interaction |
| CA2930487A1 (en) | 2007-01-16 | 2008-07-24 | Egalet Ltd. | Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i)mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| WO2008132707A1 (en) * | 2007-04-26 | 2008-11-06 | Sigmoid Pharma Limited | Manufacture of multiple minicapsules |
| EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| EP2249811A1 (en) | 2008-01-25 | 2010-11-17 | Grünenthal GmbH | Pharmaceutical dosage form |
| CN107028908A (zh) * | 2008-10-27 | 2017-08-11 | 阿尔扎公司 | 对乙酰氨基酚/曲马多口服延释剂型 |
| US20100203129A1 (en) | 2009-01-26 | 2010-08-12 | Egalet A/S | Controlled release formulations with continuous efficacy |
| WO2010088911A1 (en) | 2009-02-06 | 2010-08-12 | Egalet A/S | Pharmaceutical compositions resistant to abuse |
| CA2766179A1 (en) | 2009-06-24 | 2010-12-29 | Egalet Ltd. | Controlled release formulations |
| PE20121067A1 (es) * | 2009-07-22 | 2012-09-05 | Gruenenthal Chemie | Forma de dosificacion de liberacion controlada extruida por fusion en caliente |
| PT2838512T (pt) * | 2012-04-18 | 2018-11-09 | Gruenenthal Gmbh | Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping) |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
-
2014
- 2014-12-15 MX MX2016007848A patent/MX2016007848A/es unknown
- 2014-12-15 AU AU2014365038A patent/AU2014365038B2/en not_active Expired - Fee Related
- 2014-12-15 EP EP14811930.8A patent/EP3082781A1/en not_active Withdrawn
- 2014-12-15 CA CA2933983A patent/CA2933983A1/en not_active Abandoned
- 2014-12-15 WO PCT/EP2014/077748 patent/WO2015091352A1/en not_active Ceased
- 2014-12-15 US US14/569,817 patent/US20150164807A1/en not_active Abandoned
- 2014-12-15 JP JP2016540038A patent/JP2016540798A/ja active Pending
-
2016
- 2016-08-05 US US15/229,531 patent/US20160338976A1/en not_active Abandoned
-
2018
- 2018-01-30 US US15/883,271 patent/US20180221307A1/en not_active Abandoned
-
2019
- 2019-06-10 JP JP2019107622A patent/JP2019172688A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014365038B2 (en) | 2019-09-12 |
| US20180221307A1 (en) | 2018-08-09 |
| US20160338976A1 (en) | 2016-11-24 |
| JP2019172688A (ja) | 2019-10-10 |
| AU2014365038A1 (en) | 2016-06-30 |
| EP3082781A1 (en) | 2016-10-26 |
| WO2015091352A1 (en) | 2015-06-25 |
| US20150164807A1 (en) | 2015-06-18 |
| CA2933983A1 (en) | 2015-06-25 |
| JP2016540798A (ja) | 2016-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015016254A (es) | Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal. | |
| BR112015026549A2 (pt) | forma de dosagem à prova de violação contendo uma ou mais partículas | |
| BRPI0906467C1 (pt) | forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada | |
| EA201890130A1 (ru) | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер | |
| BR112018071155A2 (pt) | formas de dosagem de antagonista opioide de liberação modificada | |
| BR112014019988A8 (pt) | Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico | |
| PH12013501994A1 (en) | Controlled release pharmaceutical dosage forms | |
| BR112015017451A2 (pt) | formulações farmacêuticas resistentes à violação | |
| EA201071204A1 (ru) | Применение дронедарона для приготовления лекарственного средства для применения в предотвращении госпитализации в кардиологическое отделение или смертности | |
| BR112017028140A2 (pt) | formulações farmacêuticas | |
| ES2425315R1 (es) | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria | |
| CU20190060A7 (es) | Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 útiles en el tratamiento de trastornos respiratorios | |
| BR112017009521A2 (pt) | comprimido de múltiplas camadas que contém um fármaco instável à luz | |
| EP3377043A4 (en) | DEVICABLE NANOSCAL CARRIER (DNVS) FOR ADMINISTRATION THROUGH THE BLOOD-BRAIN-BARRIER, MICE AND SKIN | |
| MX363389B (es) | Composicion farmaceutica que comprende ivabradina amorfa. | |
| IL280083A (en) | A pharmaceutical dosage form that can be administered orally and with a modified release | |
| PH12016501039B1 (en) | Pharmaceutical dosage forms | |
| EA201991265A1 (ru) | Лекарственные формы с отсроченным высвобождением, содержащие диметилфумарат | |
| MX2016007848A (es) | Forma de dosificacion resistente a alteraciones con perfil de liberacion bimodal fabricado mediante co-extrusion. | |
| MX2015014307A (es) | Administracion de farmacos antiinflamatorios no esteroidales y composiciones, metodos y sistemas relacionados. | |
| IN2013MU03370A (enExample) | ||
| BR112017022335A2 (pt) | combinação de dose fixa inviolável que fornece rápida liberação de dois fármacos a partir de partículas e matriz | |
| BR112017022855A2 (pt) | combinação de dose fixa inviolável que provê liberação rápida de dois fármacos a partir de partículas e um pó | |
| EA201991007A1 (ru) | Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения | |
| PH12020500295A1 (en) | Pharmaceutical composition for prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan, and rosuvastatin, and composite preparation including the same |